OptimizeRx Co. (NASDAQ:OPRX) Shares Sold by Jane Street Group LLC

Jane Street Group LLC cut its stake in OptimizeRx Co. (NASDAQ:OPRX) by 51.2% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 21,646 shares of the company’s stock after selling 22,682 shares during the quarter. Jane Street Group LLC owned about 0.12% of OptimizeRx worth $167,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the stock. Bank of New York Mellon Corp increased its position in OptimizeRx by 9.9% during the second quarter. Bank of New York Mellon Corp now owns 111,719 shares of the company’s stock worth $1,117,000 after purchasing an additional 10,041 shares during the last quarter. Rhumbline Advisers grew its stake in shares of OptimizeRx by 9.2% in the 2nd quarter. Rhumbline Advisers now owns 31,462 shares of the company’s stock valued at $315,000 after buying an additional 2,658 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of OptimizeRx by 12.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 324,130 shares of the company’s stock worth $3,241,000 after buying an additional 35,957 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of OptimizeRx by 101.8% during the 2nd quarter. Renaissance Technologies LLC now owns 142,146 shares of the company’s stock valued at $1,421,000 after buying an additional 71,700 shares during the period. Finally, Connors Investor Services Inc. grew its position in OptimizeRx by 15.1% in the second quarter. Connors Investor Services Inc. now owns 19,107 shares of the company’s stock worth $191,000 after acquiring an additional 2,500 shares during the period. Hedge funds and other institutional investors own 76.47% of the company’s stock.

OptimizeRx Trading Down 9.5 %

Shares of OPRX stock opened at $4.85 on Tuesday. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.23 and a current ratio of 3.23. OptimizeRx Co. has a fifty-two week low of $3.78 and a fifty-two week high of $16.65. The stock has a market capitalization of $89.34 million, a P/E ratio of -3.65 and a beta of 1.36. The company has a 50 day moving average price of $5.16 and a 200 day moving average price of $7.13.

Insiders Place Their Bets

In related news, CEO William J. Febbo acquired 20,000 shares of the stock in a transaction dated Thursday, December 12th. The stock was acquired at an average cost of $5.01 per share, with a total value of $100,200.00. Following the completion of the transaction, the chief executive officer now owns 601,253 shares in the company, valued at $3,012,277.53. This represents a 3.44 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 6.10% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Stifel Nicolaus reduced their target price on OptimizeRx from $13.00 to $8.00 and set a “buy” rating on the stock in a research report on Thursday, November 14th. Lake Street Capital restated a “buy” rating and issued a $11.00 price objective on shares of OptimizeRx in a report on Tuesday, December 24th. JMP Securities lowered their target price on shares of OptimizeRx from $16.00 to $8.00 and set a “market outperform” rating for the company in a research note on Thursday, November 14th. Roth Mkm reissued a “buy” rating and issued a $16.00 price target (down from $20.00) on shares of OptimizeRx in a research note on Thursday, November 14th. Finally, William Blair reaffirmed an “outperform” rating on shares of OptimizeRx in a research report on Thursday, November 14th. Three investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, OptimizeRx currently has an average rating of “Moderate Buy” and an average target price of $9.06.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.